EML4 –ALK rearrangement in squamous cell carcinoma shows significant response to anti-ALK inhibitor drugs crizotinib and alectinib

We report anEML4 –ALK4 translocation in a 50-year-old patient with squamous cell carcinoma and an 18 pack-year smoking history. The patient had a near complete response in the CNS to alectinib treatment. Our observation suggests thatEML4 –ALK genomic testing may be clinically useful in patients with heavy smoking history.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research